2-萘甲醛,6-丁氧基- | 180135-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-萘甲醛,6-丁氧基-
• 英文名称: 6-butoxy-2-naphthaldehyde
• 英文别名: 6-Butoxynaphthalene-2-carbaldehyde
• CAS: 180135-92-6
• 化学式: C₁₅H₁₆O₂
• 分子量: 228.291
• InChiKey: NJRVCVRLLDLUMS-UHFFFAOYSA-N

物化性质

• 熔点：
  40-41 °C
• 沸点：
  376.9±15.0 °C(Predicted)
• 密度：
  1.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  D-谷氨酸 、 2-萘甲醛,6-丁氧基- 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 0.17h， 生成
  参考文献：
  名称：

  Novel Naphthalene-N-sulfonyl-d-glutamic Acid Derivatives as Inhibitors of MurD, a Key Peptidoglycan Biosynthesis Enzyme,

  摘要：

  Mur ligases have essential roles in the biosynthesis of peptidoglycan, and they represent attractive targets for the design of novel antibacterials. MurD (UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase) is the second enzyme in the series of Mur ligases, and it catalyzes the addition of D-glutamic acid (D-Glu) to the cytoplasmic intermediate UDP-N-acetylmuramoyl-L-alanine (UMA). Because of the high binding affinity of D-Glu toward MurD, we synthesized and biochemically evaluated a series of N-substituted D-Glu derivatives as potential inhibitors of MurD from E. coli, which allowed us to explore the structure-activity relationships.The substituted naphthalene-N-sulfonyl-D-Glu inhibitors, which were synthesized as potential transition state analogues, displayed IC50 values ranging from 80 to 600 microM. In addition, the high-resolution crystal structures of MurD in complex with four novel inhibitors revealed details of the binding mode of the inhibitors within the active site of MurD. Structure-activity relationships and cocrystal structures constitute an excellent starting point for further development of novel MurD inhibitors of this structural class.

  DOI：

  10.1021/jm800762u
• 作为产物：
  描述：

  (6-butoxynaphthalen-2-yl)methanol 在 sodium acetate 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 以69%的产率得到2-萘甲醛,6-丁氧基-
  参考文献：
  名称：

  Novel Naphthalene-N-sulfonyl-d-glutamic Acid Derivatives as Inhibitors of MurD, a Key Peptidoglycan Biosynthesis Enzyme,

  摘要：

  Mur ligases have essential roles in the biosynthesis of peptidoglycan, and they represent attractive targets for the design of novel antibacterials. MurD (UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase) is the second enzyme in the series of Mur ligases, and it catalyzes the addition of D-glutamic acid (D-Glu) to the cytoplasmic intermediate UDP-N-acetylmuramoyl-L-alanine (UMA). Because of the high binding affinity of D-Glu toward MurD, we synthesized and biochemically evaluated a series of N-substituted D-Glu derivatives as potential inhibitors of MurD from E. coli, which allowed us to explore the structure-activity relationships.The substituted naphthalene-N-sulfonyl-D-Glu inhibitors, which were synthesized as potential transition state analogues, displayed IC50 values ranging from 80 to 600 microM. In addition, the high-resolution crystal structures of MurD in complex with four novel inhibitors revealed details of the binding mode of the inhibitors within the active site of MurD. Structure-activity relationships and cocrystal structures constitute an excellent starting point for further development of novel MurD inhibitors of this structural class.

  DOI：

  10.1021/jm800762u

文献信息

• Arylthiosemicarbazones as antileishmanial agents
  作者：José Ignacio Manzano、Florent Cochet、Benjamin Boucherle、Verónica Gómez-Pérez、Ahcène Boumendjel、Francisco Gamarro、Marine Peuchmaur

  DOI：10.1016/j.ejmech.2016.07.014

  日期：2016.11

  the most active derivative (compound 14) showing an EC50 of 0.8 μM with very low toxicity on two different mammalian cell lines. The most relevant structural elements required for higher activity indicate that the presence of a fused bicyclic aromatic ring such as a naphthalene bearing an alkyl or an alkoxy group substituent are prerequisites. Owing to the easy synthesis, high activity and low toxicity

  在筛选过程的基础上，我们将取代的硫半脲靶向为潜在的抗菌药。我们的目标是确定有助于抗寄生虫活性的关键结构要素，这些要素可用于开发有效的药物。合成了一系列的32种化合物，并评估了其对利什曼原虫的临床相关细胞内酰胺的功效。从这些化合物中，有22种化合物的EC 50值低于10μM，活性最高的衍生物（化合物14）的EC 50值为50在两个不同的哺乳动物细胞系中，其毒性仅为0.8μM，毒性极低。更高活性所需的最相关的结构元素表明，存在稠合的双环芳环如带有烷基或烷氧基取代基的萘是先决条件。由于易于合成，高活性和低毒性，最具活性的化合物可被视为进一步开发的先导。
• Novel Chiral Bis-dipolar 6,6‘-Disubstituted Binaphthol Derivatives for Second-Order Nonlinear Optics:  Synthesis and Linear and Nonlinear Optical Properties
  作者：H.-J. Deussen、E. Hendrickx、C. Boutton、D. Krog、K. Clays、K. Bechgaard、A. Persoons、T. Bjørnholm

  DOI：10.1021/ja960076o

  日期：1996.1.1

  A number of thermally and optically stable, bis-dipolar chiral molecules based on two geometries of the binaphthol (BN) system with different acceptors/substituents have been synthesized for the first time, and the synthetic routes are reported: optically pure 6,6‘-disubstituted 2,2‘-diethoxy-1,1‘-binaphthyls R, R‘= −Br, −CHO, −CHC(CN)(COOEt), −CHC(CN)2, −CHCHCN, −CHCH(p-NO2Ph)} and optically pure

  首次合成了许多基于具有不同受体/取代基的联萘酚 (BN) 系统的两种几何结构的热和光学稳定的双偶极手性分子，并报道了合成路线：光学纯 6,6' -二取代的 2,2'-二乙氧基-1,1'-联萘 R, R'= -Br, -CHO, -CHC(CN)(COOEt), -CHC(CN)2, -CHCHCN, -CHCH(p -NO2Ph)} 和光学纯的 9,14-二取代二萘并[2,1-d:1',2'-f][1,3]dioxepins R, R' = -Br, -CHO, -CH=C (CN)(COOEt)、-CHC(CN)2、-CHCHCN、-CHCHSO2CH3、-CHCHCHO、-CHCHCHC(CN)2}。所有分子都具有两个相等的供体-受体系统，它们连接在一起形成双偶极系统。制备了两个单偶极 6-取代 2-丁氧基萘 (R = -CHC(CN)2, -CHC(CN)(COOEt)) 供体-
• Cyclic polypeptide with antibiotic activity and a process for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0729974A1

  公开（公告）日：1996-09-04

  A polypeptide compound of the following general formula : whereinR1 is acyl group, R2 is acyloxy, R3 is hydrogen and R4 is hydrogen and a pharmaceutically acceptable salt thereof, a process for its preparation and pharmaceutical compositions comprising it. The invention relates also to use of the compound for the manufacture of a medicament for treating or preventing infectious diseases.

  以下是通用式的多肽化合物： 其中，R1是酰基，R2是酰氧基，R3是氢，R4是氢，以及其药学上可接受的盐，制备该化合物的方法以及包含它的制药组合物。本发明还涉及使用该化合物制造治疗或预防传染病的药物。
• Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
  申请人：Debnath Bhunia

  公开号：US20070093476A1

  公开（公告）日：2007-04-26

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

  本发明涉及公式（I）的新化合物及其药学上可接受的盐，其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环，可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基；m和n分别表示0到6的整数；A表示O、S或键；Y选自（CH2）p′（ ）pB（ ）q′（ ）rB（ ）pD（ ）p′，其中p、q和r各自独立地表示0到6的整数；B和D分别表示S、O、NR4或键，条件是当B和D表示杂原子时，p不为零；R4表示氢、烷基、烯基、—S（O）2—R8或—C（O）R8，其中R8为烷基、烷氧基；R5和R6各自独立地表示氢、烷基、环烷基或烷氧基；R5和R6可以一起形成3-8成员环，该环可以选择性地包含选自O、S或N的一个或两个杂原子；R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式（I）化合物的制备方法，含有公式（I）化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。
• Pharmaceutical composition against Pneumocystis carinii
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0486011A2

  公开（公告）日：1992-05-20

  Use of a polypeptide compound of the formula : wherein R¹ is hydrogen or acyl group, R² is hydroxy or acyloxy, R³ is hydrogen, hydroxy or hydroxysulfonyloxy, R⁴ is hydrogen or carbamoyl, and R⁵ and R⁶ are each hydrogen or hydroxy, with proviso that (i) R² is acyloxy, when R³ is hydrogen, and (ii) R⁵ is hydrogen, when R⁶ is hydrogen, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the prevention and/or the treatment of Pneumocystis carinii infection.

  使用式 ： 其中 R¹ 是氢或酰基 R² 是羟基或酰氧基、 R³ 是氢、羟基或羟基磺酰氧基、 R⁴ 是氢或氨基甲酰基，以及 R⁵ 和 R⁶ 均为氢或羟基、 但条件是 (i) 当 R³ 为氢时，R² 为酰氧基，以及 (ii) 当 R⁵ 是氢时，R⁶ 是氢、 或其药学上可接受的盐，用于制备预防和/或治疗卡氏肺囊虫感染的药物。